BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20425460)

  • 21. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
    Cazzaniga G; Biondi A
    Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
    Cazzaniga G; Gaipa G; Rossi V; Biondi A
    Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
    Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
    Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Pan Q; Chen X; Gruhn B; Stow P; Behm FG; Pui CH; Campana D
    Leukemia; 1999 Aug; 13(8):1221-6. PubMed ID: 10450750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease quantitation in acute myeloid leukemia.
    Shook D; Coustan-Smith E; Ribeiro RC; Rubnitz JE; Campana D
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S281-5. PubMed ID: 19778853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
    Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
    Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of minimal residual disease in acute leukemia by flow cytometry.
    Campana D; Coustan-Smith E
    Cytometry; 1999 Aug; 38(4):139-52. PubMed ID: 10440852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Has MRD monitoring superseded other prognostic factors in adult ALL?
    Brüggemann M; Raff T; Kneba M
    Blood; 2012 Nov; 120(23):4470-81. PubMed ID: 23033265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Campana D; Coustan-Smith E
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
    Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
    Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease in acute lymphoblastic leukemia.
    Campana D
    Hematology Am Soc Hematol Educ Program; 2010; 2010():7-12. PubMed ID: 21239764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease monitoring by flow cytometry.
    Vidriales MB; San-Miguel JF; Orfao A; Coustan-Smith E; Campana D
    Best Pract Res Clin Haematol; 2003 Dec; 16(4):599-612. PubMed ID: 14592645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?
    Campana D
    Curr Hematol Malig Rep; 2012 Jun; 7(2):170-7. PubMed ID: 22373809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal residual disease studies by flow cytometry in acute leukemia.
    Campana D; Coustan-Smith E
    Acta Haematol; 2004; 112(1-2):8-15. PubMed ID: 15178999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.